Baker Bros. Advisors LP Kymera Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.34 Billion
- Q3 2024
A detailed history of Baker Bros. Advisors LP transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 5,995,929 shares of KYMR stock, worth $286 Million. This represents 3.04% of its overall portfolio holdings.
Number of Shares
5,995,929
Previous 5,995,928
-0.0%
Holding current value
$286 Million
Previous $179 Million
58.56%
% of portfolio
3.04%
Previous 2.38%
Shares
7 transactions
Others Institutions Holding KYMR
# of Institutions
184Shares Held
64.4MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$317 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$246 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$234 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$227 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$220 Million0.04% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.61B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...